Literature DB >> 8607797

Vitamin K2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis.

T Kameda1, K Miyazawa, Y Mori, T Yuasa, M Shiokawa, Y Nakamaru, H Mano, Y Hakeda, A Kameda, M Kumegawa.   

Abstract

In contrast to vitamin K1(VK1), vitamin K2(VK2) inhibited osteoclastic bone resorption by unfractionated bone cells and isolated osteoclasts. To investigate the mechanism of inhibition of osteoclastic bone resorption by VK2, we examined the effect of this vitamin on osteoclast apoptosis using a DNA-binding fluorescent dye, Hoechst 33258. In unfractionated bone cells and isolated osteoclasts on dentin slices, we first demonstrated that VK2 induced osteoclast apoptosis, but VK1 did not. Moreover, cycloheximide inhibited VK2-induced osteoclast apoptosis. These results suggest the possibility that VK2 inhibits osteoclastic bone resorption by targeting osteoclasts to undergo apoptosis, which leads to cell death.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607797     DOI: 10.1006/bbrc.1996.0436

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation.

Authors:  Shuying Yang; Wei Chen; Philip Stashenko; Yi-Ping Li
Journal:  J Cell Sci       Date:  2007-10-01       Impact factor: 5.285

2.  Vitamin K and metabolic bone disease.

Authors:  C Vermeer; M H Knapen; L J Schurgers
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

Review 3.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

Authors:  Satyanarayana R Pondugula; Sridhar Mani
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

4.  Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials.

Authors:  Yanfu Fang; Chuanlai Hu; Xingyong Tao; Yuhui Wan; Fangbiao Tao
Journal:  J Bone Miner Metab       Date:  2011-06-15       Impact factor: 2.626

Review 5.  Regulation of bone remodeling by vitamin K2.

Authors:  V D Myneni; E Mezey
Journal:  Oral Dis       Date:  2017-04-05       Impact factor: 3.511

6.  RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro.

Authors:  Shuying Yang; Yi-Ping Li
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

7.  Effect of GGCX gene polymorphism on the responses of serum undercarboxylated osteocalcin and bone turnover markers after treatment with vitamin K2 (menatetrenone) among postmenopausal Thai women.

Authors:  Thawee Songpatanasilp; La-or Chailurkit; Suwannee Chantprasertyothin; Boonsong Ongphiphadhanakul; Nimit Taechakraichana
Journal:  J Bone Miner Metab       Date:  2011-02-23       Impact factor: 2.626

8.  Pregnane X Receptor and Cancer: Context-Specificity is Key.

Authors:  Satyanarayana R Pondugula; Petr Pavek; Sridhar Mani
Journal:  Nucl Receptor Res       Date:  2016-06-12

9.  Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women.

Authors:  Makoto Hirao; Jun Hashimoto; Wataru Ando; Takeshi Ono; Hideki Yoshikawa
Journal:  J Bone Miner Metab       Date:  2008-05-11       Impact factor: 2.626

Review 10.  From space to Earth: advances in human physiology from 20 years of bed rest studies (1986-2006).

Authors:  A Pavy-Le Traon; M Heer; M V Narici; J Rittweger; J Vernikos
Journal:  Eur J Appl Physiol       Date:  2007-07-28       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.